Furthermore, in chronic lymphocytic leukemia, BTK inhibitors have been shown to increase CD4+ and CD8+ T cell, and significantly downregulate PD-1 and CTLA-4 (192), highlighting a potential reversal of T cell exhaustion, which could be beneficial in COVID-19. The gene discussed is BTK; the disease is COVID-19.